Bioelectronics Corp (BIEL)

[srinsocal]

"So what has this company accomplished in the past six years?"

This is off the top of my head, there are another dozen or so I am no doubt missing:

* 11/15/2018 - BioElectronics Signs a Five Country Additional Distribution Agreement with Mundipharma Indonesia, Philippines, Singapore, Thailand, Malaysia, combined population of over 400 million.

https://globenewswire.com/news-release/2018/11/15/1652277/0/en/BioElectronics-Signs-a-Five-Country-Additional-Distribution-Agreement-with-Mundipharma-Pty-Limited-South-East-Asia.html

* 11/14/2018 - ActiPatch Knee Product is available in VA Clinics
https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel-4/

* 9/2018 - ActiPatch joins with Protex for a Knee Product in 200 US CVS Stores for a Trial Rollout.
https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel-4/

* 5/31/2018 - B. Braun Medical Includes BioElectronics ActiPatch Medical Device In Its Same Day Knee and Hip Surgical Program
https://globenewswire.com/news-release/2018/05/31/1514663/0/en/B-Braun-Medical-Includes-BioElectronics-ActiPatch-Medical-Device-In-Its-Same-Day-Knee-and-Hip-Surgical-Program.html

* 4/1/2018 - United Kingdom National Health Service added ActiPatch to its Drug Tariff of approved Medical Devices.
https://globenewswire.com/news-release/2018/01/04/1283220/0/en/BioElectronics-ActiPatch-Drug-Free-Pain-Therapy-Receives-United-Kingdom-National-Health-System-Payment-Coverage.html

* 7/2018 - Mundipharma, a Billion dollar global corporation, begins ActiPatch Distribution in Australia and New Zealand

https://globenewswire.com/news-release/2018/07/23/1540578/0/en/BioElectronics-ActiPatch-Musculoskeletal-Therapy-Added-to-Mundipharma-Australia-s-Pain-Portfolio.html

* 5/30/2018 - BIEL signs Retail Deal with CARE Pharmacies, an association of 100 Independent Pharmacy Stores
http://www.actipatch.com/bioelectronics-and-care-pharmacies-to-provide-pain-consultations-and-actipatch-the-drug-free-alternative-to-opioids/

* 1/22/2018 - BIEL signs Distribution Deal with Billion dollar Performance Health which specializes in Long Term Care/Rehabilitation/Physical Therapy Markets
https://www.performancehealth.com/actipatch-advanced-24-hour-pain-relief


* 2/3/2017 – ActiPatch FDA 510k 152432 Cleared for OTC Sales in the US
This puts to rest all of the “scam device” nonsense from BIEL’s detractors. The FDA, the most stringent medical authority on the planet, says that ActiPatch is a safe and effective pain reliever. In a further confirmation of the innovative nature of this Clearance the FDA created a new Classification Product Code, PQY, for ActiPatch.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K152432

* 8/22/2017 – Keith Nalepka appointed VP of Sales and Marketing
Mr. Nalepka has 15 years of experience in placing health care products on retail shelves. He knows the store buyers and can get a meeting to present his ActiPatch pitch. BIEL has had several expert doctors on staff but never an “A List” Marketing Expert. This is a game changer. Listen to the interview linked below to get a sense of the quality of BIEL’s new VP.
https://upticknewswire.com/interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel/

http://www.bielcorp.com/bioelectronics-engages-keith-nalepka-as-vice-president-of-sales-and-marketing/

* 12/12/2017 - National US Distribution with ANDA
ANDA, formerly owned by Allergan and sold to Teva Pharmaceutical last year, has over 60,000 US healthcare business related customers. This is a key component of the goal to mainstream the ActiPatch and get it placed on retail shelves across the country.
https://finance.yahoo.com/news/bioelectronics-announces-actipatch-over-counter-133000882.html

* 5/30/2017 – Independent Migraine Study is Started
Migraine prevention is a massive potential market for ActiPatch with 36 million Americans afflicted by these debilitating headaches.
http://www.bielcorp.com/bioelectronics-announces-independent-migraine-clinical-study-migraine-prevention-using-actipatch-pulsed-shortwave-therapy/

* 11/20/2017 – Recruitment Started for Allay Menstrual Pain Study at Birmingham Women’s Hospital UK
This Study has not received a PR yet. It was mentioned in AW’s 11/20 interview. Birmingham is an NHS Foundation Hospital. “Birmingham Women's and Children's is extremely proud to be a world leader in women's and paediatric healthcare, delivering some of the most advanced treatments, complex surgical procedures and cutting-edge research and development.” Allay opens another huge market for BIEL.
https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-2/

* 8/22/2017 – ActiPatch Condensing Back/Knee/Shoulder into One Multi-Purpose Product Secured with Kinesiology Tape
This may not seem like a big deal on the surface. The cost savings of only having to stock, inventory, ship, produce packaging materials for one product are significant. Potential retailers have to love it also, only using up one shelf space rather than 3. The “K Tape” is a popular sports tape and will increase sales of the ActiPatch among the athletic demographic. The number one complaint I receive when giving samples to friends is keeping the device in place, problem now solved.
http://www.bielcorp.com/bioelectronics-president-discusses-companys-many-opportunities/

* 5/11/2017 - BioElectronics Expands into Tesco in the UK Market
A very important door has opened for BIEL with this deal as Tesco is number 5 in global retail sales with $72 billion.
http://www.bielcorp.com/bioelectronics-expands-into-tesco-in-the-uk-market/

* 2/9/2017 – ActiPatch Available on the US Amazon Website
Another key component in Mainstreaming ActiPatch. Amazon is the most popular online store in the US with $136 billion in sales last year. This was implemented 6 days after FDA Clearance.

* 2017 – First ActiPatch Licensing Deal, PharmEvo and Pain Gear
PharmEvo is marketing ActiPatch in Asia as “Pain Gear”. PharmEvo is conducting seminars to introduce doctors to “Pain Gear” and has initiated a “Pain Gear” 200 person Clinical Study. PharmEvo is in the business of providing Clinical Trials which may prove very useful to BIEL. PharmEvo is a component of the Premier Group which has business partnerships with the likes of Novartis, Sanofi, GSK and Pfizer.
https://clinicaltrials.gov/ct2/show/NCT02974023
https://www.otcmarkets.com/stock/BIEL/news/BioElectronics-Vietnam-Distributor--PharmEvo--Announces-Electroceutical-Symposium--Expansion-into-Cambodia--amp--The-Maldives?id=175011&b=y

* 12/7/2017 – BIEL Initiates US “Try and Tell” Program, Free 7 Day Trial ActiPatch
This is the same program that created thousands of repeat customers in the UK with a low marketing cost. This will also give BIEL a pool of US consumer Real World Data to reference in future regulatory submissions.
https://globenewswire.com/news-release/2017/12/07/1247461/0/en/BioElectronics-Announces-the-Launch-of-the-Try-Tell-Program.html

* 10/26/2017 – POTUS Declares Opioid Crisis a Public Health Emergency
11/6/2017 – BIEL Announces Drug Free Solution to the Opioid Crisis
BIEL promotes ActiPatch as a safe, drug free solution to chronic pain making 5,000 free Trial Devices available.
https://www.washingtonpost.com/news/post-politics/wp/2017/10/26/trump-plans-to-declare-the-opioid-crisis-a-public-health-emergency/?utm_term=.7ee1bad665ff
http://www.bielcorp.com/bioelectronics-announces-drug-free-solution-to-the-opioid-crisis-actipatch/

* 6/29/2017 – BIEL Announces Health Economics Study
This Study proves that health providers can save resources and provide improved care by using the ActiPatch to manage chronic pain. Healthcare insurers and government health agencies like the NHS should be all over this as they are constantly under pressure to provide better healthcare at a lower cost.
http://www.bielcorp.com/bioelectronics-announces-health-economics-study/

* 10/27/2017 – ActiPatch Reduces C Section Pain and Drug Use
ActiPatch users following C Section Deliveries had significantly less pain and used half the pain drugs that the control group did.
http://b2icontent.irpass.cc/812/172190.pdf?AWSAccessKeyId=1Y51NDPSZK99KT3F8VG2&Expires=1514245552&Signature=yHG8gJ%2Fc8dxYUYt2wjxe48o52Gg%3D

* 10/13/2015 - FDA Reclassification of BIEL products from Class 3 to Class 2. This confirmed that SWT Devices were Low Risk and made the 2/3/2017 OTC Clearance possible.
https://www.federalregister.gov/documents/2015/10/13/2015-25923/physical-medicine-devices-reclassification-of-shortwave-diathermy-for-all-other-uses-henceforth-to